Kyung Won Kim1, Sang Hyun Choi1, Seung Chai Jung1, Ja Youn Lee2, Ho Sung Kim1, and Seong Ho Park1
1Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, 2National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of
The current evidence in
the literature shows that the rCBV of DSC-MRI is the most widely used perfusion
MRI parameter. The rCBV can be used to predict disease progression and overall
survival in patients with recurrent malignant glioma treated with BVZ. Various perfusion
MRI parameters from DSC-MRI and DCE-MRI could play a role as pharmacodynamic
biomarkers to evaluate the drug’s anti-angiogenic effect on tumor.
